Note for reviewers
Bavencio (avelumab) for the Treatment of Metastatic Merkel Cell Carcinoma - Clinical Trials Arena
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology
An evaluation of avelumab for the treatment of genitourinary tumors
Avelumab in gastric cancer | Immunotherapy
Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development - Clinical Genitourinary Cancer
Merck Pfizer Alliance Strategy in gynecologic oncology
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | SpringerLink
Cancers | Free Full-Text | Current Perspectives in Cancer Immunotherapy | HTML
Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design | Future Oncology
761049Orig1s000
JAVELIN Gastric 300: phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as thi
Previously Treated Advanced UC | BAVENCIO® (avelumab) HCP | Safety Info
Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study | Journal for ImmunoTherapy of Cancer
Mechanism of Action | BAVENCIO® (avelumab) HCP | Safety Info
Frontiers | The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma | Immunology
Cancers | Free Full-Text | Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia | HTML
Overview of immune pathways and actions of checkpoint inhibitors. The... | Download Scientific Diagram
Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder | Urology News
Cemiplimab - an overview | ScienceDirect Topics
